成人免费xx,国产又黄又湿又刺激不卡网站,成人性视频app菠萝网站,色天天天天

  2. Stem Cell/Wnt Apoptosis Metabolic Enzyme/Protease
  3. β-catenin Bcl-2 Family Ferroptosis Endogenous Metabolite
  4. (E)-Ferulic acid

(E)-Ferulic acid  (Synonyms: 反式阿魏酸; (E)-Coniferic acid)

目錄號(hào): HY-N0060B 純度: 99.60%
COA 產(chǎn)品使用指南 技術(shù)支持

(E)-Ferulic acid 是阿魏酸 (Ferulic acid) 的異構(gòu)體，阿魏酸是芳香族化合物，在植物細(xì)胞壁中豐富。(E)-Ferulic acid 引起 β-連環(huán)蛋白 (β-catenin) 的磷酸化，導(dǎo)致蛋白酶體降解，增加促凋亡因子 Bax 的表達(dá)并降低促存活因子存活蛋白的表達(dá)。(E)-Ferulic acid 可以有效去除活性氧 (ROS) 和抑制脂質(zhì)過(guò)氧化。(E)-Ferulic acid 在人肺癌細(xì)胞系 H1299 中發(fā)揮抗增殖和抗遷移作用。

MCE 的所有產(chǎn)品僅用作科學(xué)研究或藥證申報(bào)，我們不為任何個(gè)人用途提供產(chǎn)品和服務(wù)

(E)-Ferulic acid Chemical Structure

(E)-Ferulic acid Chemical Structure

CAS No. : 537-98-4

1.  客戶無(wú)需承擔(dān)相應(yīng)的運(yùn)輸費(fèi)用。

2.  同一機(jī)構(gòu)（單位）同一產(chǎn)品試用裝僅限申領(lǐng)一次，同一機(jī)構(gòu)（單位）一年內(nèi)

     可免費(fèi)申領(lǐng)三個(gè)不同產(chǎn)品的試用裝。

3.  試用裝只面向終端客戶。

規(guī)格 價(jià)格 是否有貨 數(shù)量
10 mM * 1 mL in DMSO ￥550
In-stock
100 mg ￥500
In-stock
200 mg   詢價(jià)  
500 mg   詢價(jià)  

* Please select Quantity before adding items.

Customer Review

Other Forms of (E)-Ferulic acid:

查看 Bcl-2 Family 亞型特異性產(chǎn)品:

  • 生物活性

  • 純度 & 產(chǎn)品資料

  • 參考文獻(xiàn)

生物活性

(E)-Ferulic acid is an isomer of ferulic acid, an aromatic compound abundant in plant cell walls. (E)-Ferulic acid causes phosphorylation of β-catenin (β-catenin), leading to proteasome degradation, increasing the expression of pro-apoptotic factor Bax and reducing pro-apoptotic factor Expression of the survival factor survivin. (E)-Ferulic acid can effectively remove reactive oxygen species (ROS) and inhibit lipid peroxidation. (E)-Ferulic acid exerts antiproliferative and antimigratory effects in the human lung cancer cell line H1299.

IC50 & Target[1]

Bax

 

Microbial Metabolite

 

細(xì)胞效力
(Cellular Effect)
Cell Line Type Value Description References
A549 IC50
> 10 μM
Compound: 7
Cytotoxicity against human A549 cells after 48 hrs by SRB assay
Cytotoxicity against human A549 cells after 48 hrs by SRB assay
[PMID: 27700070]
A549 IC50
> 100 μM
Compound: 13
Cytotoxicity against human A549 cells after 72 hrs by MTT assay
Cytotoxicity against human A549 cells after 72 hrs by MTT assay
[PMID: 21696954]
A549 IC50
2.6 mM
Compound: Ferulic acid
Cytotoxicity against human A549 cells assessed as reduction in cell viability measured after 48 hrs by FMCA assay
Cytotoxicity against human A549 cells assessed as reduction in cell viability measured after 48 hrs by FMCA assay
[PMID: 27162124]
A549 IC50
3.1 mM
Compound: Ferulic acid
Cytotoxicity against human A549 cells assessed as reduction in cell viability measured after 48 hrs by MTT assay
Cytotoxicity against human A549 cells assessed as reduction in cell viability measured after 48 hrs by MTT assay
[PMID: 27162124]
A549 IC50
3.2 mM
Compound: Ferulic acid
Cytotoxicity against human A549 cells assessed as reduction in cell viability measured after 48 hrs by luminescence-based ATP assay
Cytotoxicity against human A549 cells assessed as reduction in cell viability measured after 48 hrs by luminescence-based ATP assay
[PMID: 27162124]
BT-549 IC50
> 10 μM
Compound: 7
Cytotoxicity against human BT549 cells after 48 hrs by SRB assay
Cytotoxicity against human BT549 cells after 48 hrs by SRB assay
[PMID: 27700070]
BT-549 IC50
1.2 μM
Compound: 1
Antiproliferative activity against human BT549 cells after 24 hrs by MTT assay
Antiproliferative activity against human BT549 cells after 24 hrs by MTT assay
[PMID: 29144746]
BV-2 EC50
> 10 μM
Compound: 2
Antiinflammatory activity in mouse BV2 cells assessed as inhibition of LPS-induced microglial activation after 24 hrs by Griess reagent based assay
Antiinflammatory activity in mouse BV2 cells assessed as inhibition of LPS-induced microglial activation after 24 hrs by Griess reagent based assay
[PMID: 29407994]
BV-2 IC50
> 50 μM
Compound: 7
Antineuroinflammatory activity in mouse BV2 cells assessed as inhibition of LPS-induced nitric oxide production after 24 hrs by Griess assay
Antineuroinflammatory activity in mouse BV2 cells assessed as inhibition of LPS-induced nitric oxide production after 24 hrs by Griess assay
[PMID: 27700070]
C2BBe1 IC50
> 200 μM
Compound: 2; FA
Cytotoxicity against human C2BBe1 cells assessed as reduction in cell proliferation after 24 hrs by sulforhodamine B assay
Cytotoxicity against human C2BBe1 cells assessed as reduction in cell proliferation after 24 hrs by sulforhodamine B assay
[PMID: 27290693]
C2BBe1 IC50
> 200 μM
Compound: 2; FA
Cytotoxicity against human C2BBe1 cells assessed as reduction in cell proliferation after 48 hrs by sulforhodamine B assay
Cytotoxicity against human C2BBe1 cells assessed as reduction in cell proliferation after 48 hrs by sulforhodamine B assay
[PMID: 27290693]
C2BBe1 IC50
> 200 μM
Compound: 2; FA
Cytotoxicity against human C2BBe1 cells assessed as reduction in cell proliferation after 72 hrs by sulforhodamine B assay
Cytotoxicity against human C2BBe1 cells assessed as reduction in cell proliferation after 72 hrs by sulforhodamine B assay
[PMID: 27290693]
C2BBe1 IC50
> 200 μM
Compound: 2; FA
Cytotoxicity against human C2BBe1 cells assessed as reduction in cell proliferation after 96 hrs by sulforhodamine B assay
Cytotoxicity against human C2BBe1 cells assessed as reduction in cell proliferation after 96 hrs by sulforhodamine B assay
[PMID: 27290693]
HT-22 EC50
> 10 μM
Compound: 2
Neuroprotective activity against IAA-induced ischemia in mouse HT22 cells assessed as increase in cell viability cotreated with IAA for 2 hrs followed by IAA wash out measured after 24 hrs by MTT assay
Neuroprotective activity against IAA-induced ischemia in mouse HT22 cells assessed as increase in cell viability cotreated with IAA for 2 hrs followed by IAA wash out measured after 24 hrs by MTT assay
[PMID: 29407994]
K562 IC50
> 1000 μM
Compound: Ferulic acid
Cytotoxicity against human K562 cells after 5 days by XTT assay
Cytotoxicity against human K562 cells after 5 days by XTT assay
[PMID: 18076140]
LoVo IC50
95 μM
Compound: 13
Cytotoxicity against human LoVo cells after 72 hrs by MTT assay
Cytotoxicity against human LoVo cells after 72 hrs by MTT assay
[PMID: 21696954]
MCF7 IC50
0.36 μM
Compound: FerA
Antiproliferative activity against human MCF7 cells assessed as cell viability after 24 hrs
Antiproliferative activity against human MCF7 cells assessed as cell viability after 24 hrs
[PMID: 33139111]
MDA-MB-231 IC50
0.5 μM
Compound: 1
Antiproliferative activity against human MDA-MB-231 cells after 24 hrs by MTT assay
Antiproliferative activity against human MDA-MB-231 cells after 24 hrs by MTT assay
[PMID: 29144746]
MDA-MB-231 IC50
15 μM
Compound: FerA
Antiproliferative activity against human MDA-MB-231 cells assessed as cell viability after 24 hrs
Antiproliferative activity against human MDA-MB-231 cells assessed as cell viability after 24 hrs
[PMID: 33139111]
MT4 CC50
> 10 μM
Compound: 8
Cytotoxicity against human MT4 cells assessed as reduction in cell viability after 3 days by CytoTox-Glo assay
Cytotoxicity against human MT4 cells assessed as reduction in cell viability after 3 days by CytoTox-Glo assay
[PMID: 26756779]
MT4 EC50
> 10 μM
Compound: 8
Antiviral activity against HIV1 NL4-3 infected in human MT4 cells assessed as reduction in viral replication measured on day 3 post infection by luciferase reporter gene assay
Antiviral activity against HIV1 NL4-3 infected in human MT4 cells assessed as reduction in viral replication measured on day 3 post infection by luciferase reporter gene assay
[PMID: 26756779]
Neutrophil IC50
200 μM
Compound: 2; FA
Inhibition of phorbol myristate acetate-induced human neutrophils oxidative burst assessed as reduction in luminol oxidation preincubated for 5 mins followed by PMA addition measured after 15 mins by chemiluminescence assay
Inhibition of phorbol myristate acetate-induced human neutrophils oxidative burst assessed as reduction in luminol oxidation preincubated for 5 mins followed by PMA addition measured after 15 mins by chemiluminescence assay
[PMID: 27290693]
PC-3 IC50
> 100 μM
Compound: 13
Cytotoxicity against human PC3 cells after 72 hrs by MTT assay
Cytotoxicity against human PC3 cells after 72 hrs by MTT assay
[PMID: 21696954]
RAW264.7 IC50
> 100 μM
Compound: 12
Antiinflammatory activity in mouse RAW264.7 cells assessed as decrease in LPS-induced NO production after 24 hrs by Griess assay
Antiinflammatory activity in mouse RAW264.7 cells assessed as decrease in LPS-induced NO production after 24 hrs by Griess assay
[PMID: 25666824]
SH-SY5Y IC50
11.82 μM
Compound: ferulic acid
Antioxidant activity in human SH-SY5Y cells assessed as reduction in H2O2-induced reactive oxygen species formation measured after 24 hrs by DCFH-DA probe based fluorescence assay
Antioxidant activity in human SH-SY5Y cells assessed as reduction in H2O2-induced reactive oxygen species formation measured after 24 hrs by DCFH-DA probe based fluorescence assay
[PMID: 28282613]
SK-MEL-2 IC50
> 10 μM
Compound: 7
Cytotoxicity against human SK-MEL-2 cells after 48 hrs by SRB assay
Cytotoxicity against human SK-MEL-2 cells after 48 hrs by SRB assay
[PMID: 27700070]
SK-MEL-28 IC50
> 100 μM
Compound: 13
Cytotoxicity against human SK-MEL-28 cells after 72 hrs by MTT assay
Cytotoxicity against human SK-MEL-28 cells after 72 hrs by MTT assay
[PMID: 21696954]
SK-OV-3 IC50
> 10 μM
Compound: 7
Cytotoxicity against human SKOV3 cells after 48 hrs by SRB assay
Cytotoxicity against human SKOV3 cells after 48 hrs by SRB assay
[PMID: 27700070]
TT IC50
150 μM
Compound: Ferulic acid
Cytotoxicity against human TT cells by trypan blue dye-based assay
Cytotoxicity against human TT cells by trypan blue dye-based assay
[PMID: 31336310]
U-373MG ATCC IC50
> 100 μM
Compound: 13
Cytotoxicity against human U373 cells after 72 hrs by MTT assay
Cytotoxicity against human U373 cells after 72 hrs by MTT assay
[PMID: 21696954]
WiDr IC50
> 200 μM
Compound: 2; FA
Cytotoxicity against human WiDr cells assessed as reduction in cell proliferation after 24 hrs by sulforhodamine B assay
Cytotoxicity against human WiDr cells assessed as reduction in cell proliferation after 24 hrs by sulforhodamine B assay
[PMID: 27290693]
WiDr IC50
> 200 μM
Compound: 2; FA
Cytotoxicity against human WiDr cells assessed as reduction in cell proliferation after 48 hrs by sulforhodamine B assay
Cytotoxicity against human WiDr cells assessed as reduction in cell proliferation after 48 hrs by sulforhodamine B assay
[PMID: 27290693]
WiDr IC50
> 200 μM
Compound: 2; FA
Cytotoxicity against human WiDr cells assessed as reduction in cell proliferation after 72 hrs by sulforhodamine B assay
Cytotoxicity against human WiDr cells assessed as reduction in cell proliferation after 72 hrs by sulforhodamine B assay
[PMID: 27290693]
WiDr IC50
> 200 μM
Compound: 2; FA
Cytotoxicity against human WiDr cells assessed as reduction in cell proliferation after 96 hrs by sulforhodamine B assay
Cytotoxicity against human WiDr cells assessed as reduction in cell proliferation after 96 hrs by sulforhodamine B assay
[PMID: 27290693]
體外研究
(In Vitro)

Ferulic acid (FA) 是一種新型成纖維細(xì)胞生長(zhǎng)因子受體 1 (FGFR1) 抑制劑，對(duì) FGFR1 和 FGFR2 的 IC50 分別為 3.78 和 12.5 μM。FeruLic acid 對(duì) FGFR1 表現(xiàn)出很強(qiáng)的抑制活性，在 1 μM 時(shí)抑制率為 92%。在 5 至 40 μM 的 Ferulic acid 處理 24 小時(shí)后，F(xiàn)GF1 刺激的 HUVEC 的增殖顯著降低。高達(dá) 20 μM 的 Ferulic acid 不會(huì)發(fā)揮顯著的細(xì)胞活力，但與對(duì)照相比，超過(guò) 30 μM 的 Ferulic acid 在 HUVEC 中表現(xiàn)出細(xì)胞毒性作用。Ferulic acid 以劑量依賴性方式抑制 FGF1 誘導(dǎo)的 HUVEC 遷移和侵襲。Ferulic acid 顯著抑制 FGF1 誘導(dǎo)的 PI3K 和 Akt 磷酸化。Ferulic acid 顯著抑制 FGF1 刺激的 MMP-2 和 MMP-9 表達(dá)[1]。

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Cell Proliferation Assay[1]

Cell Line: H1299
Concentration: 0.03-0.6 mM
Incubation Time: 24 h, 48 h
Result: Low dose had no significant cytotoxic effect, but cytotoxicity was observed with 0.3 and 0.6 mM for 48 h.

Apoptosis Analysis[1]

Cell Line: H1299
Concentration: 0.03-0.6 mM
Incubation Time: 48 h
Result: Caused the arrest of the cell cycle at G0/G1 and a decrease in the percentage of the G2/M phase. And induced a significant increase in apoptotic populations. with 0.6 mM

Cell Migration Assay [1]

Cell Line: H1299
Concentration: 0.03-0.6 mM
Incubation Time: 16 h, (48 h)
Result: Inhibited cell migration and invasion. by reducing the activity of MMP?2 and MMP?9 and increased β-catenin phosphorylation at Thr41/Ser45 but did not affect β-catenin protein levels.
體內(nèi)研究
(In Vivo)

用 Ferulic acid (FA) 處理可有效抑制 FGF1 誘導(dǎo)的新血管形成。發(fā)現(xiàn)與用 DMSO 處理的對(duì)應(yīng)物相比，F(xiàn)erulic acid 的胃內(nèi)給藥顯著抑制了腫瘤體積和腫瘤重量。此外，F(xiàn)erulic acid 處理耐受性良好，賦形劑組和 FA 處理組的體重沒(méi)有顯著差異[1]?？诜?Ferulic acid (0.01、0.1、1 或 10 mg/kg) 可顯著縮短強(qiáng)迫游泳試驗(yàn) (FST) 和懸尾試驗(yàn) (TST) 中的不動(dòng)時(shí)間，而在曠場(chǎng)試驗(yàn)中無(wú)影響。結(jié)果表明 Ferulic acid (0.001 mg/kg，po) 的給藥增強(qiáng)了 Fluoxetine (HY-B0102) (5 mg/kg，po) 在 TST 中的抗抑郁樣作用[2]。

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model: Male Wister Albino Rat model[2]
Dosage: 100 mg/kg
Administration: i.g, once a day for 21 days
Result: Decreased tamoxifen-induced elevated enzyme activities of AST, ALT, and ALP and ameliorated the decrease in the hepatic enzyme activities.
分子量

194.18

Formula

C10H10O4
CAS 號(hào)
性狀

固體

顏色

White to off-white

中文名稱

反式-阿魏酸
結(jié)構(gòu)分類
初始來(lái)源
運(yùn)輸條件

Room temperature in continental US; may vary elsewhere.
儲(chǔ)存方式

Store at room temperature 3 years

In solvent -80°C 2 years
-20°C 1 year
溶解性數(shù)據(jù)
細(xì)胞實(shí)驗(yàn)： 

DMSO 中的溶解度 : 100 mg/mL (514.99 mM; 超聲助溶; 吸濕的 DMSO 對(duì)產(chǎn)品的溶解度有顯著影響，請(qǐng)使用新開封的 DMSO)

配制儲(chǔ)備液
濃度 溶劑體積 質(zhì)量 1 mg 5 mg 10 mg
1 mM 5.1499 mL 25.7493 mL 51.4986 mL
5 mM 1.0300 mL 5.1499 mL 10.2997 mL
查看完整儲(chǔ)備液配制表

* 請(qǐng)根據(jù)產(chǎn)品在不同溶劑中的溶解度選擇合適的溶劑配制儲(chǔ)備液；一旦配成溶液，請(qǐng)分裝保存，避免反復(fù)凍融造成的產(chǎn)品失效。
儲(chǔ)備液的保存方式和期限：-80°C, 2 years; -20°C, 1 year。-80°C儲(chǔ)存時(shí)，請(qǐng)?jiān)?年內(nèi)使用，-20°C儲(chǔ)存時(shí)，請(qǐng)?jiān)?年內(nèi)使用。

  • 摩爾計(jì)算器

  • 稀釋計(jì)算器

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

質(zhì)量
=
濃度
×
體積
×
分子量 *

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2

濃度 (start)

C1

×
體積 (start)

V1

=
濃度 (final)

C2

×
體積 (final)

V2

動(dòng)物實(shí)驗(yàn)：

請(qǐng)根據(jù)您的 實(shí)驗(yàn)動(dòng)物和給藥方式 選擇適當(dāng)?shù)娜芙夥桨浮?

以下溶解方案都請(qǐng)先按照 In Vitro 方式配制澄清的儲(chǔ)備液，再依次添加助溶劑：
——為保證實(shí)驗(yàn)結(jié)果的可靠性，澄清的儲(chǔ)備液可以根據(jù)儲(chǔ)存條件，適當(dāng)保存；體內(nèi)實(shí)驗(yàn)的工作液，建議您現(xiàn)用現(xiàn)配，當(dāng)天使用；
以下溶劑前顯示的百分比是指該溶劑在您配制終溶液中的體積占比；如在配制過(guò)程中出現(xiàn)沉淀、析出現(xiàn)象，可以通過(guò)加熱和/或超聲的方式助溶

  • 方案 一

    請(qǐng)依序添加每種溶劑： 10% DMSO    40% PEG300    5% Tween-80    45% Saline

    Solubility: ≥ 2.5 mg/mL (12.87 mM); 澄清溶液

    此方案可獲得 ≥ 2.5 mg/mL（飽和度未知）的澄清溶液。

    以 1 mL 工作液為例，取 100 μL 25.0 mg/mL 的澄清 DMSO 儲(chǔ)備液加到 400 μL PEG300 中，混合均勻；再向上述體系中加入 50 μL Tween-80，混合均勻；然后再繼續(xù)加入 450 μL 生理鹽水 定容至 1 mL。

    生理鹽水的配制：將 0.9 g 氯化鈉，溶解于 ddH?O 并定容至 100 mL，可以得到澄清透明的生理鹽水溶液。
  • 方案 二

    請(qǐng)依序添加每種溶劑： 10% DMSO    90% (20% SBE-β-CD in Saline)

    Solubility: ≥ 2.5 mg/mL (12.87 mM); 澄清溶液

    此方案可獲得 ≥ 2.5 mg/mL（飽和度未知）的澄清溶液。

    以 1 mL 工作液為例，取 100 μL 25.0 mg/mL 的澄清 DMSO 儲(chǔ)備液加到 900 μL 20% 的 SBE-β-CD 生理鹽水水溶液 中，混合均勻。

    2 g SBE-β-CD（磺丁基醚 β-環(huán)糊精）粉末定容于 10 mL 的生理鹽水中，完全溶解至澄清透明。
動(dòng)物溶解方案計(jì)算器
請(qǐng)輸入動(dòng)物實(shí)驗(yàn)的基本信息：

給藥劑量

mg/kg

動(dòng)物的平均體重

g

每只動(dòng)物的給藥體積

μL

動(dòng)物數(shù)量

只
由于實(shí)驗(yàn)過(guò)程有損耗，建議您多配一只動(dòng)物的量
請(qǐng)輸入您的動(dòng)物體內(nèi)配方組成：
%
DMSO +
% 
+
%
Tween-80 +
%
Saline
如果您的動(dòng)物是免疫缺陷鼠或者體弱鼠，建議 DMSO 中的在最后工作液體系中的占比盡量不超過(guò) 2%。
方案所需 助溶劑 包括：DMSO， ，均可在 MCE 網(wǎng)站選購(gòu)。 ，Tween 80，均可在 MCE 網(wǎng)站選購(gòu)。
計(jì)算結(jié)果
工作液所需濃度 : mg/mL
儲(chǔ)備液配制方法 : mg 藥物溶于 μL  DMSO（母液濃度為 mg/mL）。
您所需的儲(chǔ)備液濃度超過(guò)該產(chǎn)品的實(shí)測(cè)溶解度，以下方案僅供參考，如有需要，請(qǐng)與 MCE 中國(guó)技術(shù)支持聯(lián)系。
動(dòng)物實(shí)驗(yàn)體內(nèi)工作液的配制方法 : 取 μL DMSO 儲(chǔ)備液，加入 μL 。 μL ，混合均勻至澄清，再加 μL Tween 80，混合均勻至澄清，再加 μL 生理鹽水。
連續(xù)給藥周期超過(guò)半月以上，請(qǐng)謹(jǐn)慎選擇該方案。
請(qǐng)確保第一步儲(chǔ)備液溶解至澄清狀態(tài)，從左到右依次添加助溶劑。您可采用超聲加熱 （超聲清洗儀，建議頻次 20-40 kHz），渦旋吹打等方式輔助溶解。
純度 & 產(chǎn)品資料

純度: 99.89%

參考文獻(xiàn)

完整儲(chǔ)備液配制表

* 請(qǐng)根據(jù)產(chǎn)品在不同溶劑中的溶解度選擇合適的溶劑配制儲(chǔ)備液；一旦配成溶液，請(qǐng)分裝保存，避免反復(fù)凍融造成的產(chǎn)品失效。
儲(chǔ)備液的保存方式和期限：-80°C, 2 years; -20°C, 1 year。-80°C儲(chǔ)存時(shí)，請(qǐng)?jiān)?年內(nèi)使用，-20°C儲(chǔ)存時(shí)，請(qǐng)?jiān)?年內(nèi)使用。

可選溶劑 濃度 溶劑體積 質(zhì)量 1 mg 5 mg 10 mg 25 mg
DMSO 1 mM 5.1499 mL 25.7493 mL 51.4986 mL 128.7465 mL
5 mM 1.0300 mL 5.1499 mL 10.2997 mL 25.7493 mL
10 mM 0.5150 mL 2.5749 mL 5.1499 mL 12.8747 mL
15 mM 0.3433 mL 1.7166 mL 3.4332 mL 8.5831 mL
20 mM 0.2575 mL 1.2875 mL 2.5749 mL 6.4373 mL
25 mM 0.2060 mL 1.0300 mL 2.0599 mL 5.1499 mL
30 mM 0.1717 mL 0.8583 mL 1.7166 mL 4.2916 mL
40 mM 0.1287 mL 0.6437 mL 1.2875 mL 3.2187 mL
50 mM 0.1030 mL 0.5150 mL 1.0300 mL 2.5749 mL
60 mM 0.0858 mL 0.4292 mL 0.8583 mL 2.1458 mL
80 mM 0.0644 mL 0.3219 mL 0.6437 mL 1.6093 mL
100 mM 0.0515 mL 0.2575 mL 0.5150 mL 1.2875 mL
Help & FAQs
  • Do most proteins show cross-species activity?

    Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

您最近查看的產(chǎn)品:

Your information is safe with us. * Required Fields.

   產(chǎn)品名稱：

  

* 需求量：

* 客戶姓名：

 

* Email：

* 電話：

 

* 公司或機(jī)構(gòu)名稱：

   留言給我們：

Bulk Inquiry

Inquiry Information

產(chǎn)品名稱：
(E)-Ferulic acid
目錄號(hào)：
HY-N0060B
需求量：